# Study of STK-012 Alone and With Other Treatments in Patients With Advanced Lung Cancer and Other Cancers

Source: https://onco.cc/trials/nct05098132/  
OnCo record `nct05098132` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 1/2 trial of Pemetrexed, Carboplatin in non-small-cell lung cancer and small-cell lung cancer, run by Synthekine, now recruiting.

## Summary

Study of STK-012 Alone and With Other Treatments in Patients With Advanced Lung Cancer and Other Cancers is a phase 1/2 interventional study registered as NCT05098132 by Synthekine, with 364 participants planned, started 2022-01-25 and due to reach its primary completion in 2029-01. Interventions recorded: STK-012, pembrolizumab KEYTRUDA®, pemetrexed, carboplatin. Conditions listed: Advanced Solid Tumor, Non Small Cell Lung Cancer, Untreated Advanced NSCLC, 1st Line NSCLC. No results are recorded here; the registry entry is the source.

## Fields

- Kind: Trial
- Status: recruiting
- Last checked: 2026-09-16
- Tags: ctgov-ingest
- Registry id: NCT05098132
- Phase: 1/2
- Setting: A Phase 1/2 Study to Evaluate STK-012 as a Single Agent and in Combination Therapy in Subjects With Front-line Advanced NSCLC and Other Selected Indications
- Sponsor: Synthekine
- Enrolled: 364

## Sources

- ClinicalTrials.gov NCT05098132: https://clinicaltrials.gov/study/NCT05098132

## Connected records

- cancers: [Non-small-cell lung cancer](https://onco.cc/cancers/nsclc/), [Small-cell lung cancer](https://onco.cc/cancers/sclc/)
- drugs: [Carboplatin](https://onco.cc/drugs/carboplatin/), [Pemetrexed](https://onco.cc/drugs/pemetrexed/)

---
JSON: https://onco.cc/api/v1/entities/nct05098132.json